Dr. Reinhard Dummer on Toxicities with Binimetinib in Metastatic Melanoma

Source: OncLive, August 2016

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the toxicities of binimetinib in patients with NRAS-mutant metastatic melanoma.

Binimetinib results in many of the same toxicities as other MEK inhibitors, said Dummer. In the NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma, most adverse were mild and manageable, he said.

However side effects do occur with binimetinib, including muscular toxicities that are reflected by an elevation by the muscle enzyme CPK.